Insider Selling: Arcutis Biotherapeutics (NASDAQ:ARQT) Insider Sells $220,116.00 in Stock

Posted by Stanley Muller on Aug 16th, 2026

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Get Free Report) insider Patrick Burnett sold 8,300 shares of Arcutis Biotherapeutics stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $26.52, for a total value of $220,116.00. Following the sale, the insider owned 119,289 shares in the company, valued at $3,163,544.28. This trade represents a 6.51% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Patrick Burnett also recently made the following trade(s):

On Wednesday, August 12th, Patrick Burnett sold 6,700 shares of Arcutis Biotherapeutics stock. The shares were sold at an average price of $26.08, for a total value of $174,736.00.
On Monday, August 3rd, Patrick Burnett sold 955 shares of Arcutis Biotherapeutics stock. The stock was sold at an average price of $26.12, for a total value of $24,944.60.

Arcutis Biotherapeutics Trading Up 1.4%

NASDAQ:ARQT opened at $26.19 on Friday. The company has a market capitalization of $3.29 billion, a PE ratio of 124.72 and a beta of 1.49. Arcutis Biotherapeutics, Inc. has a 52-week low of $15.10 and a 52-week high of $31.77. The stock’s 50 day moving average price is $26.52 and its 200 day moving average price is $24.69. The company has a quick ratio of 2.67, a current ratio of 2.92 and a debt-to-equity ratio of 0.46.

Arcutis Biotherapeutics (NASDAQ:ARQT – Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $0.11 earnings per share for the quarter, beating analysts’ consensus estimates of $0.06 by $0.05. The company had revenue of $129.86 million during the quarter, compared to analysts’ expectations of $118.85 million. Arcutis Biotherapeutics had a return on equity of 15.05% and a net margin of 6.15%. On average, research analysts anticipate that Arcutis Biotherapeutics, Inc. will post 0.4 EPS for the current year.

Wall Street Analyst Weigh In

ARQT has been the subject of a number of recent research reports. Needham & Company LLC increased their price target on shares of Arcutis Biotherapeutics from $36.00 to $40.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Guggenheim lifted their price objective on shares of Arcutis Biotherapeutics from $35.00 to $38.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Wall Street Zen raised shares of Arcutis Biotherapeutics from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 8th. Morgan Stanley increased their target price on shares of Arcutis Biotherapeutics from $34.00 to $38.00 and gave the stock an “overweight” rating in a research note on Thursday, August 6th. Finally, Weiss Ratings raised Arcutis Biotherapeutics from a “sell (d-)” rating to a “hold (c-)” rating in a report on Thursday, August 6th. Six analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $35.57.

View Our Latest Stock Analysis on ARQT

Institutional Investors Weigh In On Arcutis Biotherapeutics

Hedge funds have recently modified their holdings of the stock. BlackRock Inc. acquired a new position in Arcutis Biotherapeutics in the 2nd quarter valued at $276,502,000. Suvretta Capital Management LLC raised its position in Arcutis Biotherapeutics by 14.2% during the 4th quarter. Suvretta Capital Management LLC now owns 11,964,000 shares of the company’s stock worth $347,435,000 after buying an additional 1,486,000 shares during the last quarter. Jupiter Topco LLC acquired a new stake in shares of Arcutis Biotherapeutics in the 2nd quarter worth $36,989,000. Price T Rowe Associates Inc. MD lifted its stake in shares of Arcutis Biotherapeutics by 1,228.4% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,166,348 shares of the company’s stock worth $33,872,000 after acquiring an additional 1,078,546 shares during the period. Finally, Healthcare of Ontario Pension Plan Trust Fund purchased a new stake in shares of Arcutis Biotherapeutics in the fourth quarter valued at about $26,136,000.

Arcutis Biotherapeutics Company Profile

(Get Free Report)

Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for immuno-inflammatory skin diseases. The company’s research and development efforts center on targeted treatments that address the underlying biology of conditions such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis and vitiligo. Arcutis employs a precision-medicine approach to deliver topical therapies designed to improve efficacy and tolerability compared with existing treatment options.

In August 2022, Arcutis received U.S.